A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Vericiguat (VERQUVO)

Soluble Guanylate Cyclase Stimulator class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2021-02-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$78.8M in CY2024 Part D spend78K claims · 21K beneficiaries · 329 plans surveyed

Lowest NADAC
$22.70/unit
9 NDCs benchmarked, lowest of all strengths.
Average NADAC
$22.74
Across all dosage forms in distribution.
Highest NADAC
$22.76
Range is tight.
Plans with PA
669 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Vericiguat used for?

Vericiguat is a Soluble Guanylate Cyclase Stimulator medication tracked in Medicare Part D.

Is there a generic for Vericiguat?

No. Vericiguat is brand-only with no generic equivalents currently in market.

How much does my plan pay for Vericiguat?

Across 329 Part D plans, Vericiguat averages $22.74/unit (NADAC). Lowest available: $22.70/unit. Highest in distribution: $22.76/unit.

Is Vericiguat on the FDA shortage list?

No. Vericiguat is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Soluble Guanylate Cyclase Stimulator1 alternative in D1
01
Riociguat
Brand: Adempas
Lowest NADAC
1Generic mfrs
$1.08BCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file (9 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.